Metagenomi Statistics
Total Valuation
Metagenomi has a market cap or net worth of $71.31 million. The enterprise value is -$90.74 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Metagenomi has 37.53 million shares outstanding. The number of shares has increased by 149.45% in one year.
| Current Share Class | 37.53M |
| Shares Outstanding | 37.53M |
| Shares Change (YoY) | +149.45% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 11.19% |
| Owned by Institutions (%) | 21.40% |
| Float | 25.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.13 |
| Forward PS | 2.05 |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.36, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.36 |
| Quick Ratio | 6.23 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.45% and return on invested capital (ROIC) is -20.63%.
| Return on Equity (ROE) | -37.45% |
| Return on Assets (ROA) | -17.44% |
| Return on Invested Capital (ROIC) | -20.63% |
| Return on Capital Employed (ROCE) | -38.41% |
| Revenue Per Employee | $167,168 |
| Profits Per Employee | -$431,277 |
| Employee Count | 202 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -43.08% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 2.13 |
| Relative Strength Index (RSI) | 41.39 |
| Average Volume (20 Days) | 624,155 |
Short Selling Information
The latest short interest is 1.39 million, so 3.71% of the outstanding shares have been sold short.
| Short Interest | 1.39M |
| Short Previous Month | 1.33M |
| Short % of Shares Out | 3.71% |
| Short % of Float | 5.54% |
| Short Ratio (days to cover) | 1.59 |
Income Statement
In the last 12 months, Metagenomi had revenue of $33.77 million and -$87.12 million in losses. Loss per share was -$2.35.
| Revenue | 33.77M |
| Gross Profit | -63.30M |
| Operating Income | -91.81M |
| Pretax Income | n/a |
| Net Income | -87.12M |
| EBITDA | -86.30M |
| EBIT | -91.81M |
| Loss Per Share | -$2.35 |
Full Income StatementBalance Sheet
The company has $204.99 million in cash and $42.99 million in debt, giving a net cash position of $162.00 million or $4.32 per share.
| Cash & Cash Equivalents | 204.99M |
| Total Debt | 42.99M |
| Net Cash | 162.00M |
| Net Cash Per Share | $4.32 |
| Equity (Book Value) | 195.83M |
| Book Value Per Share | 5.22 |
| Working Capital | 178.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$97.01 million and capital expenditures -$1.95 million, giving a free cash flow of -$98.96 million.
| Operating Cash Flow | -97.01M |
| Capital Expenditures | -1.95M |
| Free Cash Flow | -98.96M |
| FCF Per Share | -$2.64 |
Full Cash Flow StatementMargins
Gross margin is -187.46%, with operating and profit margins of -271.89% and -257.99%.
| Gross Margin | -187.46% |
| Operating Margin | -271.89% |
| Pretax Margin | -267.38% |
| Profit Margin | -257.99% |
| EBITDA Margin | -255.55% |
| EBIT Margin | -271.89% |
| FCF Margin | n/a |
Dividends & Yields
Metagenomi does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -149.45% |
| Shareholder Yield | -149.45% |
| Earnings Yield | -122.24% |
| FCF Yield | -138.85% |
Analyst Forecast
The average price target for Metagenomi is $12.00, which is 531.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 531.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Metagenomi has an Altman Z-Score of -0.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.86 |
| Piotroski F-Score | 1 |
